Lipid-lowering therapy in patients with peripheral arterial disease

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 9, Issue 4, 2004, Pages 271-277

  Ebrahimi, Ramin ^a,b   Saleh, Jahandar R ^a   Toggart, Edward J ^a   Hayatdavoudi, Baubac ^a   Wolf, Christopher J ^a   Wadhani, Nitin N ^a   Shah, Atman P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

HMG CoA inhibitors; Hypocholesterolemic drugs; Lipid therapy; Peripheral arterial disease

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DOCOSAHEXAENOIC ACID; EZETIMIBE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ICOSAPENTAENOIC ACID; NICOTINIC ACID; NICOTINYL ALCOHOL; PRAVASTATIN; PROBUCOL; SIMVASTATIN; STATINE DERIVATIVE; SULODEXIDE; XANTHINOL NICOTINATE;

ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET; DISEASE COURSE; HUMAN; ILEUM BYPASS; META ANALYSIS; MORTALITY; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PERIPHERAL VASCULAR DISEASES; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME;

EID: 12344253206     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840400900407     Document Type: Review

References (35)

1. Barndt R Jr, Blankenhorn DH, Crawford DW, et al. Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients. Ann Intern Med 86:139-146, 1977
2. Duffield RG, Lewis B, Miller NE, et al. Treatment of hyperlipidemia retards progression of symptomatic femoral atherosclerosis. A randomized controlled trial. Lancet 2:639-642, 1983
3. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of Simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 81:333-335, 1998
4. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 71:510-515, 1985
5. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286:1317-1324, 2001
6. Kannel WB, Skinner JJJ, Schwartz MJ, et al. Intermittent claudication. Incidence in the Framingham Study. Circulation 40:875-883, 1970
7. Makin AJ, Silverman SH, Lip GY. Ethnicity and peripheral vascular disease. Int J Clin Pract 56(9):645-648, 2002
8. McDermott MM, Greenland P, Liu K, et al. Sex differences in peripheral arterial disease: Leg symptoms and physical functioning. J Am Geriatr Soc 51(2):222-228, 2003
9. Hirsch AT. Claudication as an 'orphan disease': rational and goal of drug therapy for peripheral arterial disease. Vasc Med 1:37-42, 1996
10. Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med 1:60-64, 1996
11. Weitz JI, Byrne J, Clagett G, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review. Circulation 94:3026-3049, 1996
12. Hiatt WR. Preventing atherothrombotic events in peripheral arterial disease: The use of antiplatelet therapy.[Review] J Intern Med 251(3):193-206, 2002
13. Newman AB, Shemanski L, Monolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular health study. Arteriosclerosis Thromb Vasc Biol 19:538-545, 1999
14. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348:1329-1339, 1996
15. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. New Engl J Med 344:1608-1621, 2001
16. Mc Kenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 87:119-128, 1991
17. Hertzer NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 199:223-233, 1984
18. Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischemia. A review article. J Cardiovasc Surg 30:50-57, 1989
19. McDermott MM, Mehta S, Liu K, et al. Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J Gen Intern Med 14:173-181, 1999
20. Ost CR, Stenson S. Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid. Scand J Clin Lab Invest 99(Suppl):241-245, 1967
21. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database Syst Rev (2):CD000123, 2000
22. Walldius G, Carlson LA, Erikson U, et al. Development of femoral atherosclerosis in hypercholesterolemic patients with cholestyramine and probucol/placebo: Probucol Quantitative Regression trial (PQRST): A status report. Am J Cardiol 62:37B-43B, 1988
23. Mondillo S, Ballo P, Barbati R, et al. Effects of Simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 14(5):359-364, 2003
24. Corsi C, Bocci L, Cipriani C, et al. The effectiveness of glycosaminoglycans in peripheral vascular disease therapy: A clinical and experimental trial. J Int Med Res 13:40-47, 1985
25. Gans ROB, Bilo H, Weersink E, et al. Fish oil supplementation in patients with stable claudication. Am J Surg 160:490-495, 1990
26. Papamichael CM, Lekakis JP, Stamatelopoulos KS, et al. Ankle brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol 86:615-618, 2000
27. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108(12):1481-1486, 2003
28. Nye R, Macbeth W. The treatment of intermittent claudication with beta-pyridyl carbinol over two years. Atherosclerosis 17:95-106, 1973
29. Davis E, Rozov H. Xanthinol nicotinate in peripheral vascular disease. Practitioner 215:793-798, 1975
30. Farmer JA, Gotto AM. The Heart Protection Study: Expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 92(suppl):3i-9i, 2003
31. Buchwald H, Bourdages HR, Campos CT, et al. Impact of cholesterol reduction on peripheral arterial disease in the Program on Surgical Control of the Hyperlipidemias (POSCH). Surgery 120:672-679, 1996
32. Blann AD, Gurney D, Hughes E, et al. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am J Cardiol 88(1):A7-8, 89-92, 2001
33. Stamler JS, Loh E, Roddy MA, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 91:1314-1319, 1994
34. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower extremity peripheral arterial disease. Circulation 107:757-761, 2003
35. Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults, Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486-2497, 2001